Global CDMO
MEDIPOST provides global-standard cell therapy manufacturing technology.
MEDIPOST offers its clients, who are planning overseas clinical trials through the CDMO facility at OmniaBio in North America, cell therapy production technology that meets global standards and an ‘all-in-one package’ including the development, manufacturing, quality testing, and licensing support of advanced biopharmaceuticals.
· Located in Toronto, Canada
– OmniaBio is a global CDMO acquired by MEDIPOST in 2022 and located in Toronto, a hub for health care research/research personnel
– OminiaBio offers development/manufacturing services to cell and gene therapy developers that want to speed-up clinical trials to enter the U.S. market
– Owns Best-in-Class cell/gene therapy PD and manufacturing infrastructure
– Owns pool of GMP Quality/ manufacturing/ PD experts through university-industry collaboration
· GMP facilities and equipment (2019)
– 8 Cell therapy suites
– 2 Vial vector suites
· OmniaBio’s new plant (Omnia B)
– A new GMP facility expected to be fully operational by 2024 and designed to start global CDMO services for cell/gene therapy
– Gross square footage: 80,000 sq.ft
– The facility will have 15 Suites(Clean rooms) and manage PD, MSAT, and QC
· OmniaBio GMP Facility
– Location : Toronto, Canada
– Business : Cell & Gene Therapy, Global CMO/CDMO
· MEDIPOST GMP Center
– Location : Guro District, Seoul
– Business : Cell Therapy, domestic CMO/CDMO